Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July 2024. With its earlier launch, much of the real-world data at AD/PD ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Roche’s Brainshuttle tech shows promise in Alzheimer’s treatment, enabling better drug delivery to the brain in trials.

Ralph Carmona, a 74-year-old Portland man who has Alzheimer's, says he is a living example of the value of medical research.

The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...

The legislation would require insurance plans provided through the state’s system to cover FDA-approved treatments for ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...